Nanobiotix Released 2025 Financials and Corporate Presentation
Nanobiotix has announced its full-year 2025 operational and financial results via a webcast. The company also published an updated corporate presentation.
Nanobiotix, a company specializing in cancer treatments, has released its operational and financial performance for the full year 2025. The information was presented during a webcast for investors held on April 1, 2026.
The event provided stakeholders with an update on the company's progress in research and development, as well as its commercialization strategy. Attendees received insights into Nanobiotix's advancements in the field of oncology.
In addition to the financial update, Nanobiotix published a revised corporate presentation. This document offers comprehensive details on the company's technology, ongoing clinical trials, and future outlook. The presentation is accessible on Nanobiotix's investor relations website.
The company is developing a novel cancer therapy based on its proprietary nano-buss technology, designed to enhance the efficacy of radiotherapy within cancer cells. Nanobiotix is actively seeking collaborations and participants for its clinical studies.
Inquiries regarding Nanobiotix's technology, partnerships, or clinical trials can be directed to the company's investor relations team.